Session 121 - 12th CROI

Home

Session 121 Poster Abstracts
Impact of Drug Resistance on Virologic Response and Clinical Outcomes
Friday, 1:30 - 3:30 pm
Hall A

705	Validation of Clinically Relevant Breakpoints for HIV-1 Phenotypic Resistance Data B Winters¹, A Rinehart², J Montaner³, P Harrigan³, D Castor⁴, S Hammer⁵, B Wasikowski⁶, M Miller⁷, S Emery⁸, F van Leth⁹, P Robinson¹⁰, J Baxter¹¹, B Gazzard¹², A Pozniak¹³, and L Bacheler² ¹Virco BVBA, Mechelen, Belgium; ²Virco Lab, Inc, Durham, NC, USA; ³British Columbia Ctr for Excellence in HIV/AIDS, Vancouver, Canada; ⁴New York Academy of Med, NY, USA; ⁵Columbia Univ, New York, NY, USA; ⁶xLeo, Inc, Durham, NC, USA; ⁷Gilead Sci, Foster City, CA, USA; ⁸Natl Ctr in HIV Epidemiology and Clin Res, Univ of New South Wales, Sydney, Australia; ⁹Intl Antiviral Therapy Evaluation Ctr, Amsterdam, The Netherlands; ¹⁰Boehringer Ingelheim Pharma Inc, Ridgefield, CT, USA; ¹¹Robert Wood Johnson Med Sch, Camden, NJ, USA; ¹²Chelsea and Westminster Hlthcare NHS Trust, London, UK; and ¹³Chelsea & Westminster Hlthcare NHS Trust, London, UK
706	in vivo Determination of Stavudine Activity in the Presence of TAM Franco Maggiolo*, A Callegaro, D Ripamonti, S Nemis, A Acerbis, A Goglio, and F Suter Hosp Riuniti di Bergamo
707	in vivo Determination of Tenofovir Antiviral Effect in the Presence of TAM Franco Maggiolo*, A Callegaro, G Gregis, G Quinzan, C Arici, A Goglio, and F Suter Hosp Riuniti di Bergamo, Italy
708	Thymidine Analog Mutation Profiles: Factors Associated with Acquiring Specific Profiles and Their Effect on Virologic Response to Therapy Alessandro Cozzi-Lepri*¹, L Ruiz^3,4, C Loveday², A Phillips¹, B Clotet^4,7, P Reiss⁵, J Lundgren⁶, and EuroSIDA Study Group ¹Royal Free and Univ Coll Med Sch, London, UK; ²Intl Clin Virology Ctr, Great Missenden Bucks, UK; ³Univ Autónoma de Barcelona, Spain; ⁴Hosp Germans Trias i Pujol, Barcelona, Spain; ⁵Academic Med Ctr, Univ of Amsterdam, The Netherlands; ⁶Copenhagen HIV Prgm, Hvidovre Hosp, Denmark; and ⁷irsiCaixa Fndn, Badalona, Spain
709	Type-1 Thymidine-associated Mutations but Not K65R Mutation Play a Role in Determining Virologic Failure to Combined Rescue Therapy with Tenofovir and Stavudine Andrea Antinori*¹, M Trotta¹, P Nasta², T Bini³, S Bonora⁴, A Castagna⁵, T Quirino⁶, S Landonio³, S Merli³, V Tozzi¹, M Zaccarelli¹, G Di Perri⁴, M Andreoni⁷, C Perno⁷, and G Carosi² ¹INMI, IRCCS L Spallanzani, Rome, Italy; ²Univ degli Studi, Brescia, Italy; ³Hosp Luigi Sacco, Milan, Italy; ⁴Univ degli Studi, Torino, Italy; ⁵Hosp San Raffaele, Univ Vita e Salute, Milan, Italy; ⁶General Hosp, Busto Arsizio, Italy; and ⁷Univ of Rome 'Tor Vergata', Italy
710	Successful Rescue Therapy in Patients Developing K65R on Tenofovir Containing Regimens: Long-term Follow-up Roland Landman*¹, D Descamps², A Trylesinski³, A Benalycherif¹, P Girard⁴, P Yeni², M Bentata⁵, C Michelet⁶, P de Truchis⁷, B Bonnet⁸, C Katlama⁹, G Peytavin², N Margot¹⁰, M Miller¹⁰, and F Brun Vezinet² ¹Hosp Bichat-Claude Bernard, Paris, France; ²Hosp Bichat-Claude Bernard, Paris, France; ³Gilead Sci, Foster City, CA, USA; ⁴Hosp St-Antoine, Paris, France; ⁵Hosp Avicenne, Bobigny, France; ⁶Hosp Pontchaillou, Rennes, France; ⁷Hosp Raymond Poincaré, Garches, France; ⁸Hopital Hotel Dieu, Nantes, France; ⁹Hosp Pitie-Salpetriere, Paris, France; and ¹⁰Gilead Sci, Foster City, CA, USA
711	The Influence of Baseline Protease Inhibitor Mutations on the Efficacy of Ritonavir-Boosted Atazanavir, Atazanavir plus Saquinavir, and Lopinavir/Ritonavir in Patients Who Have Experienced Virologic Failure on Multiple HAART Regimens Margaret Johnson*¹, E DeJesus², C Rodriguez³, L Nieto-Cisneros⁴, A Rightmire⁵, C McLaren⁶, and L Odeshoo⁶ ¹Royal Free Hosp, London, UK; ²IDC Res Initiative, Altamonte Springs, FL, USA; ³Hosp Argerich, Buenos Aires, Argentina; ⁴Hosp Gabriel Mancera, IMSS, Mexico City, Mexico; ⁵Bristol-Myers Squibb, Hopewell, NJ, USA; and ⁶Bristol-Myers Squibb, Wallingford, CT, USA
712	Drug Resistance Is Associated with an Increased Risk of Death in Patients First Starting HAART Robert S Hogg*¹, D Bangsberg², C Alexander¹, S Bonner¹, B Yip¹, E Wood¹, W Dong¹, B Wynhoven¹, J Montaner¹, and P Harrigan¹ ¹British Columbia Ctr for Excellence in HIV/AIDS, Vancouver, Canada and ²Epidemiology and Prevention Interventions Center, San Francisco Gen Hosp, CA, USA